ONCOLOGY Nurse Edition April 2009, Vol 23 No 4

Publication
Article
Oncology Nurse EditionONCOLOGY Nurse Edition Vol 23 No 4
Volume 23
Issue 4

Main Articles

Departments

Patient Information

  • Understanding and Managing Nausea and Vomiting

 

 

Articles in this issue
ONCOLOGY Nurse Edition April 2009, Vol 23 No 4
Hypertension Management in the Era of Targeted Therapies for Cancer
An Alkylating Agent for CLL and NHL
Vesicant Extravasation From an Implanted Venous Access Port
Survivorship Care: Essential Components and Models of Delivery
Cardiotoxicities of Breast Cancer Treatment
Improving the End-of-Life Experience
When Hospice Is the Best Option: An Opportunity to Redefine Goals
Living Well: A Goal for All Patients
The Patient With Cancer-Related Dyspnea
Related Videos
video 8 - "Treatment Landscape for NSCLC With EGFR Exon 20 Insertion Mutations"
Video 7 - "Second-Line Treatment of Patients With EGFR-Mutated NSCLC"
A panel of 5 experts on liver cancer
A panel of 5 experts on liver cancer
A panel of 5 experts on liver cancer
A panel of 5 experts on liver cancer
Estelamari Rodriguez, MD, MPH, an expert on lung cancer
Christine Bestvina, MD, an expert on lung cancer
Caitlin Costello, MD, with the Oncology Brothers
Related Content
Phase 2 data support the potential of replacing cisplatin with nab-paclitaxel as a backbone therapy for those with muscle-invasive bladder cancer.

Nivolumab Combo Shows Efficacy, Safety in Muscle-Invasive Bladder Cancer

May 10th 2024
Article

Phase 2 data support the potential of replacing cisplatin with nab-paclitaxel as a backbone therapy for those with muscle-invasive bladder cancer.

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

May 6th 2024
Podcast

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

FDA Grants Fast Track Designation to SNB-101 in Small Cell Lung Cancer

FDA Grants Fast Track Designation to SNB-101 in Small Cell Lung Cancer

May 10th 2024
Article

Treatment with SNB-101 previously demonstrated tolerability among patients with solid tumors in a phase 1 trial.

Timothy Chen, MD, highlights how technologies such as ZAP-X and proton therapy may improve outcomes for patients with cancer.

Applying Novel Radiotherapy Technology for Brain Tumors and Other Cancers

April 29th 2024
Podcast

Timothy Chen, MD, highlights how technologies such as ZAP-X and proton therapy may improve outcomes for patients with cancer.

Investigators found that imatinib maintenance therapy for 6 years reduced the risk of recurrence in patients with gastrointestinal stromal tumors.

Six-Year Imatinib Maintenance Therapy Reduces Recurrence Risk in GIST

May 9th 2024
Article

Investigators found that imatinib maintenance therapy for 6 years reduced the risk of recurrence in patients with gastrointestinal stromal tumors.

Phase 2 data support the use of fuzuloparib with or without apatinib in HER2-negative metastatic breast cancer harboring BRCA1/2 germline mutations.

Fuzuloparib ± Apatinib Improves PFS in BRCA+ Metastatic Breast Cancer

May 9th 2024
Article

Phase 2 data support the use of fuzuloparib with or without apatinib in HER2-negative metastatic breast cancer harboring BRCA1/2 germline mutations.